Bispecific antibodies for cancer immunotherapy: Current perspectives

被引：94

作者：

Müller D. ^{[1
]}

Kontermann R.E. ^{[1
]}

机构：

[1] Institut für Zellbiologie und Immunologie, Universität Stuttgart, 70569 Stuttgart

来源：

BioDrugs | 2010年 / 24卷 / 2期

关键词：

Antibodies; general; Bispecific-antibodies; Cancer; Immunotherapies;

D O I：

10.2165/11530960-000000000-00000

中图分类号：

学科分类号：

摘要：

The concept of using bispecific antibodies to retarget immune effector cells for cancer therapy was conceived more than 20 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe adverse effects and immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy or dual targeting approaches in order to improve binding, selectivity, and efficacy. This review summarizes recent progress in the development of bispecific antibodies and describes some new concepts developed for cancer immunotherapy. © 2010 Adis Data Information BV.

引用

页码：89 / 98

页数：9

共 60 条

[1]

Muller D., Kontermann R.E., Bispecific antibodies, Handbook of therapeutic antibodies, pp. 345-378, (2007)

[2]

Muller D., Kontermann R.E., Recombinant bispecific antibodies for cellular cancer immunotherapy, Curr Opin Mol Ther, 9, pp. 319-326, (2007)

[3]

Chames P., Baty D., Bispecific antibodies for cancer therapy, Curr Opin Drug Discov Develop, 12, pp. 276-283, (2009)

[4]

Ruf P., Lindhofer H., Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody, Blood, 98, pp. 2526-2534, (2001)

[5]

Kontermann R.E., Alternative antibody formats, Curr Opin Mol Ther

[6]

Wu C., Ying H., Grinnell C., Et al., Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin, Nat Biotechnol, 25, pp. 1290-1297, (2007)

[7]

Baeuerle P.A., Kufer P., Bargou R., BiTE: Teaching antibodies to engage T-cells for cancer therapy, Curr Opin Mol Ther, 11, pp. 22-30, (2009)

[8]

Kellner C., Bruenke J., Stieglmaier J., Et al., A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells, J Immunother, 31, pp. 871-884, (2008)

[9]

Rossi E.A., Sharkey R.M., McBride W., Et al., Development of new mutlivalent-bispecific agents for pretargeting tumor localization and therapy, Clin Cancer Res, 9, (2003)

[10]

Kontermann R.E., Recombinant bispecific antibodies for cancer therapy, Acta Pharmacol Sin, 26, pp. 1-9, (2005)

← 1 2 3 4 5 6 →